In continuation of our Letter dated 2th February, 2026 we wish to inform you that a meeting of the Board of Directors of the Company was held on Saturday, 7th February, 2026 at Shop No 1 ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Tejnaksh Healthcare's board, which met on February 7, 2026, approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, along with the limited review report from auditors Maheshwari & Co. On a consolidated basis, Q3 revenue from operations came in at Rs 261.62 lakhs (down from Rs 297.81 lakhs in the previous quarter and Rs 318.98 lakhs a year ago), with profit after tax of Rs 28.82 lakhs (vs Rs 33.15 lakhs in Q2 and Rs 55.54 lakhs in Q3 FY25). For the nine months ended December 2025, consolidated revenue fell to Rs 823.40 lakhs from Rs 968.22 lakhs a year earlier, while profit dropped sharply to Rs 83.24 lakhs from Rs 180.72 lakhs, pushing EPS down to Rs 0.41 from Rs 0.90. Standalone numbers showed a similar trend, with nine-month profit nearly halving to Rs 87.56 lakhs from Rs 186.61 lakhs.
Shareholders should note a clear deterioration in performance, with both revenues and profits declining sequentially and year-on-year for both standalone and consolidated businesses, leading to a near halving of nine-month EPS. This weak earnings print is likely to weigh negatively on near-term investor sentiment, though the company is debt-light with healthy reserves of over Rs 1,500 lakhs.